Fig 1.
The image presented here, depicts a comparative illustration of EGFR and its mutated form, EGFR VIII, formed after the deletion of 2–7 exons in the extracellular domain of parent protein molecule.
Due to this mutation, the EGFR becomes more oncogenic. However, the study given her cannot validate that in meningioma but introduce further questions about role of EGFR vIII in oncogenicity and tumorogenecity in tumor growth and formation. It also indicates towards the probable need of advanced techniques to detect the EGFR vIII in meningioma tumor. Moreover, if EGFR vIII can be used as therapeutic target is still in question.
Fig 2.
These figures show the expression of Ki-67 in two different grades of meningioma (a) expression of Ki-67 in meningioma grade-I; (b) Expression of Ki-67 in meningioma grade-II.
Table 1.
Patients clinical characteristics (n = 56).
Table 2.
Role of Ki67 marker in different grades of meningioma (Student’s t test).
Fig 3.
These figures show intensity scores of immunohistochemical staining (A) Meningioma stained with anti-EGFR showing negative staining in meningioma grade I (B) 1+ weak staining (C) 2+ moderate staining (D) 3+ strong staining (E) Meningioma stained with anti-EGFR showing negative staining in meningioma grade II (F) 1+ weak staining (G) 2+ moderate staining (H) 3+ strong staining. Original magnification for all images was 40 ×. Images are arranged as follows, on the left side (A), (B), (C), and (D) are of MG grade I. On the right side (E), (F), (G), and (H) belongs to meningioma grade II.
Fig 4.
Percentage of EGFR vIII staining in the human meningioma grade I and II by histopathological classification.
Tumor sections were analyzed concerning the percent of each sample exhibiting staining for EGFR vIII. The percentages of immunoreactive cells (staining percentage) were estimated by inspection and scored from +1 to +3, benign meningioma (grade I) 1+ 0% (0); 2+ 29.4% (10) and 3+ 70.6% (24) of a samples had higher intensity respectively. And atypical meningioma (grade II) were stained as follows, 1+ (weakly stained) 100% (22); 2+ (moderately stained) 0% (0); 3+ (strongly stained) 0% (0).
Fig 5.
Generation of EGFRvIII− and EGFRvIII+ sublines as determined via FACS.
MG Grade I representing 25.8% EGFRvIII (Alexa flour 488) positive cells (SSC vs Alexa Flour 488) while Grade II representing 11.1% EGFRvIII (Alexa flour 488) positive cells (SSC vs Alexa Flour 488). There is about 2 folds decrease in EGFR V3+ cells in grade II as compared to grade I. Unlabelled cells were used as controls in both grade I and grade II.
Table 3.
EGFR vIII staining intensity/expression of meningioma samples (grade I and II), n (%).
Table 4.
Expression of FACS EGFR VIII positive cells (%) in meningioma grade I and II patients.